Diuretics And Heart Failure Technique - Medscape Reference

close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel

processing....

Tools & Reference>Clinical Procedures Diuretics and Heart Failure Technique Updated: Nov 18, 2024

• Author: Eitan A Friedman, MD; Chief Editor: Karlheinz Peter, MD, PhD more...

• Share
• Print
• Feedback

Close

• Facebook
• Twitter
• LinkedIn
• WhatsApp
• Email

Sections Diuretics and Heart Failure

• Sections Diuretics and Heart Failure
• Overview
  • Background
  • Technical Considerations
  • Outcomes
  • Show All
• Technique
  • Outpatient
  • Inpatient
  • Potassium-sparing Diuretics
  • Nondiuretic Alternatives
  • Show All
• Medication
  • Aldosterone Antagonists, Selective
  • Antiglaucoma, Carbonic Anhydrase Inhibitors
  • Diuretics, Loop
  • Diuretics, Other
  • Diuretics, Thiazide
  • Diuretics, Potassium-Sparing
  • Vasopressin Antagonists
  • Show All
• References

Technique

Outpatient

Diuretics are a mainstay of the outpatient management of heart failure. Most patients with advanced heart failure require diuretics daily in order to maintain fluid balance. Sodium restriction, typically less than 2 g daily, is essential. [11] Each clinical visit should include weight measurement and targeted questioning regarding diuretic effectiveness. Electrolytes and renal function need to be frequently monitored during diuretic titration and at least every 6 months in patients on stable long-term diuretics.

One of the most common outpatient regimens is once daily furosemide. However, given its serum half-life of only 1.5 hours, the kidney is not exposed to diuretics for an extended period of time and is still avidly retaining sodium and free water. More frequent dosing intervals of furosemide should thus be considered. Patients who become less responsive to a specific diuretic may benefit from switching to another agent in the same class. An increase in effective dose may indicate diuretic resistance. Additionally, failure to restrict dietary sodium intake and usage of nonsteroidal anti-inflammatory drugs (NSAIDs) must also be considered.

Patients with high medical literacy can be instructed to weigh themselves at home daily and titrate their own diuretic doses. If they record weight gain of 2-3 lb over a 24-hour period, they can take an extra dose of diuretic and call their physician. Such an approach helps detect hypervolemia before symptoms develop and may prevent full exacerbations.

A cohort study that included 2761 patients hospitalized for acute heart failure who were divided in early and delayed “door-to-diuretic times” (≤60 min and >60 min) reported that the early or delayed timing of diuretics initiation was not associated with clinical outcomes. [12]

Next:

Inpatient

In the inpatient treatment of acute decompensated heart failure, an intravenous (IV) dose of a loop diuretic is typically given. IV dosing has more rapid onset of action and predictable pharmacokinetics than oral dosing. Limited data are available to direct the use of diuretics, and most recommendations are based on consensus opinions. [13] When choosing the dosing regimen, consider both the dose and frequency. A threshold effect is common. For example, if a 40 mg furosemide bolus fails to result in significant diuresis, continuing to use the 40 mg dose every 6 hours is unlikely to be effective. Many would recommend doubling the dose to 80 mg, assuring its efficacy, and then choosing a dosing interval.

The serum half-life of the drug must be considered when selecting the dosing interval. For example, the serum half-life of IV furosemide is 1.5 hours; therefore, by 6 hours (4 half-lives), the effects of furosemide would be expected to be minimal. Renal failure frequently accompanies heart failure exacerbations. The selected dose needs to be progressively higher as the GFR decreases. Diuretic dose has proven to be a reliable indicator of heart failure severity. [14]

Relatively few trials have explored differences in efficacy among the loop diuretics in treating heart failure. Among open-label studies comparing torsemide to furosemide, one demonstrated decreased mortality, one showed decreased heart failure hospitalizations, and two found improvement in New York Heart Association functional class. [15, 16, 17] A more recent open-label study in which patients hospitalized with heart failure were randomly assigned to torsemide or furosemide showed similar mortality (26%). [18] One small open-label study comparing bumetanide to furosemide revealed no significant difference in signs or symptoms of heart failure. [19]

The multicenter DOSE study explored the effects of high dose versus low dose diuretic use in acute decompensated heart failure. High-dose furosemide led to greater diuresis and improvement in overall symptoms compared to a low-dose regimen. Renal dysfunction was more common in the high-dose group, although at 60 days follow-up, creatinine levels were similar in both groups. [20]

Continuous diuretic infusion is an alternative to bolus injection. Continuous infusion prevents the rapid fluctuations in intravascular volume status and concomitant sympathetic activation that commonly occurs after a bolus dose. Continuous infusion also ensures that the nephrons are continuously exposed to a therapeutic dose of diuretic. Furthermore, continuous infusion may lead to an overall lower diuretic dose, limiting toxicity such as ototoxicity.

The DOSE study was the most comprehensive trial to investigate the effects of continuous versus bolus diuretic dosing regimens in acute decompensated heart failure. [20] No difference in the primary end-point of patient symptoms or change in serum creatinine concentration was seen. However, the total dose of diuretics was lower in the continuous infusion arm.

In patients who have limited response either to higher bolus dosing or continuous infusion of loop diuretics, a thiazide diuretic can be added to achieve what has been termed sequential nephron blockade. Common agents include chlorothiazide, hydrochlorothiazide, and the thiazide-like diuretic metolazone. Adjunctive use of thiazides can overcome the resistance to loop diuretics associated with reactive hypertrophy of the distal convoluted tubule (DCT) of the nephron. By blocking the Na-Cl channel in the DCT, they hinder the avid sodium reabsorption that limits loop diuretic efficacy. Numerous studies have demonstrated augmented diuresis with a combined loop/thiazide diuretic regimen. [21] Across studies, the efficacy appears similar regardless of the specific thiazide or loop diuretics used.

Many physicians dose metolazone 30 minutes prior to dosing the loop diuretic to ensure the distal Na-Cl channel is already blocked when the increased sodium reaches the DCT. However, no evidence suggests that timing of metolazone dose has any effect. Moreover, particularly in edematous patients the absorption of metolazone varies and can take several hours to reach peak concentration. [22] For patients who have a significantly reduced GFR or diuretic resistance, sequential nephron blockade can be extended to include the proximal convoluted tubule, with acetazolamide, and the cortical collecting duct, with spironolactone. No clinical study demonstrated whether such a regimen improves diuresis, symptoms, or clinical outcomes.

Combining loop and thiazide diuretics does carry certain risks that are necessary to consider. The markedly increased sodium delivery to the cortical collecting duct leads to a significant potassium wasting. Frequently monitor potassium, often twice daily, and aggressively replete. Excessive urine chloride loss can lead to hypochloremic metabolic alkalosis. Additionally, the rapid decrease in intravascular volume can precipitate hypotension. Increases in serum creatinine frequently occur secondary to prerenal physiology. Temporary discontinuation of both the loop and thiazide diuretics may be necessary in the setting of massive diuresis or potassium loss.

Determining the appropriate end-point for diuresis can be challenging. Clinical symptoms, (dyspnea, edema), exam (jugular venous pulse, edema, crackles), and laboratory values should be used to guide therapy. Often physicians will stop active diuresis once the blood urea nitrogen (BUN) levels begin to rise. The patient’s weight should be measured at this point and be documented as the patients euvolemic (or “dry”) weight. Prior to discharge, the diuretics should be converted from an intravenous to an oral regimen. Because oral efficacy can be hard to predict, monitor the patients in the hospital for a day on the oral regimen to determine the dose efficacy.

Previous Next:

Potassium-sparing Diuretics

The aldosterone antagonists spironolactone and eplerenone have been shown to be effective therapies for chronic heart failure, based on the RALES and EPHESUS studies. [23, 24] Although these agents are technically diuretics, at the low doses studied, the primary effect of these drugs lies in their inhibition of aldosterone rather than diuretic action. They may be beneficial in counteracting the hypokalemia from loop diuretics. They may also enhance diuresis in the resistant patient, but there is no outcomes data to support the use of higher dose of aldosterone antagonist diuretics in heart failure.

Previous Next:

Nondiuretic Alternatives

Vasopressin antagonists

The vasopressin antagonist tolvaptan has been studied in patients with heart failure. By inhibiting the vasopressin receptor in the distal nephron, it leads to an aquaresis. The medication is particularly appealing because it both causes volume loss and combats the hyponatremia which is common in heart failure and a poor prognostic indicator. The EVEREST trial explored the effects of short term use of tolvaptan versus placebo in addition to standard therapy (including diuretics) in acute heart failure. [25] Serum sodium level increased with tolvaptan use. Patients treated with tolvaptan also had more rapid improvement in symptoms, although no significant difference was noted by day 7 or discharge. The appropriate use of tolvaptan among the currently available treatments for acute heart failure remains to be determined.

Ultrafiltration

Because diuretic use in advanced heart failure can be particularly challenging, ultrafiltration (UF) has been studied as an alternative means for reducing intravascular volume and managing pulmonary congestion. The UNLOAD study was a randomized controlled trial of UF versus intravenous diuretics in patients with acute decompensated heart failure. [26] At 48 hours, greater weight loss was noted with UF, although dyspnea scores were similar. Additionally, no significant difference was noted in the percentage of patients who developed a rise in creatinine. Ninety-day hospital readmission was lower in patients who had received UF. Further studies need to address the optimum UF regimen, as well as safety and efficacy, before UF can be recommended routinely in the management of heart failure.

The following are contraindications to UF:

• Evidence of hemodynamic instability
• Acute coronary syndromes, including myocardial infarction and unstable angina
• Serum creatinine level of >3.0 mg/dL
• Hematocrit of >45%

Previous Medication

References

1. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024 Feb 20. 149 (8):e347-e913. [QxMD MEDLINE Link]. [Full Text].

2. Goldberg RJ, Spencer FA, Szklo-Coxe M, Tisminetzky M, Yarzebski J, Lessard D. Symptom presentation in patients hospitalized with acute heart failure. Clin Cardiol. 2010 Jun. 33(6):E73-80. [QxMD MEDLINE Link].

3. Brater DC. Diuretic therapy. N Engl J Med. 1998 Aug 6. 339(6):387-95. [QxMD MEDLINE Link].

4. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction?. Ann Pharmacother. 2005 Feb. 39(2):290-301. [QxMD MEDLINE Link].

5. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009. 113(1):12-9. [QxMD MEDLINE Link].

6. Wright SP, Verouhis D, Gamble G, Swedberg K, Sharpe N, Doughty RN. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail. 2003 Mar. 5(2):201-9. [QxMD MEDLINE Link].

7. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 Feb 17. 53(7):589-96. [QxMD MEDLINE Link].

8. Poole-Wilson PA. Treatment of acute heart failure: out with the old, in with the new. JAMA. 2002 Mar 27. 287(12):1578-80. [QxMD MEDLINE Link].

9. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985 Jul. 103(1):1-6. [QxMD MEDLINE Link].

10. Bikdeli B, Strait KM, Dharmarajan K, Li SX, Mody P, Partovian C, et al. Intravenous fluids in acute decompensated heart failure. JACC Heart Fail. 2015 Feb. 3(2):127-33. [QxMD MEDLINE Link].

11. [Guideline] Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022 May. 28 (5):e1-e167. [QxMD MEDLINE Link].

12. Park JJ, Kim SH, Oh IY, Choi DJ, Park HA, Cho HJ, et al. The Effect of Door-to-Diuretic Time on Clinical Outcomes in Patients With Acute Heart Failure. JACC Heart Fail. 2018 Apr. 6 (4):286-294. [QxMD MEDLINE Link].

13. , Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun. 16(6):e1-194. [QxMD MEDLINE Link].

14. Andersson C, Norgaard ML, Hansen PR, Fosbol EL, Schmiegelow M, Weeke P. Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail. 2010 Dec. 12(12):1333-8. [QxMD MEDLINE Link].

15. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001 Nov. 111(7):513-20. [QxMD MEDLINE Link].

16. Cosin J, Diez J. TORIC investigators. Torasemide in chronic heart failure:results of the TORIC study. Eur J Heart Fail. 2002 Aug;4(4):507-13. Erratum in:. Eur J Heart Fail. 2002 Oct. 4(5):667.

17. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. Eur J Heart Fail. 2003 Dec. 5(6):793-801. [QxMD MEDLINE Link].

18. Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023 Jan 17. 329 (3):214-23. [QxMD MEDLINE Link]. [Full Text].

19. Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. J Clin Pharmacol. 1981 Nov-Dec. 21(11-12 Pt 2):688-90. [QxMD MEDLINE Link].

20. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3. 364(9):797-805. [QxMD MEDLINE Link].

21. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010 Nov 2. 56(19):1527-34. [QxMD MEDLINE Link].

22. Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther. 1974 Aug. 16(2):322-9. [QxMD MEDLINE Link].

23. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2. 341(10):709-17. [QxMD MEDLINE Link].

24. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3. 348(14):1309-21. [QxMD MEDLINE Link].

25. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 Mar 28. 297(12):1332-43. [QxMD MEDLINE Link].

26. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13. 49(6):675-83. [QxMD MEDLINE Link].

Media Gallery of 0

Tables

Back to List

Contributor Information and Disclosures

Author

Eitan A Friedman, MD Fellow, Cardiovascular Medicine, Vanderbilt University Medical CenterEitan A Friedman, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Student Association/FoundationDisclosure: Nothing to disclose.

Chief Editor

Karlheinz Peter, MD, PhD Professor of Medicine, Monash University; Head of Centre of Thrombosis and Myocardial Infarction, Head of Division of Atherothrombosis and Vascular Biology, Associate Director, Baker Heart Research Institute; Interventional Cardiologist, The Alfred Hospital, AustraliaKarlheinz Peter, MD, PhD is a member of the following medical societies: American Heart Association, German Cardiac Society, Cardiac Society of Australia and New ZealandDisclosure: Nothing to disclose.

Close

What would you like to print?

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article

• Sections Diuretics and Heart Failure
• Overview
  • Background
  • Technical Considerations
  • Outcomes
  • Show All
• Technique
  • Outpatient
  • Inpatient
  • Potassium-sparing Diuretics
  • Nondiuretic Alternatives
  • Show All
• Medication
  • Aldosterone Antagonists, Selective
  • Antiglaucoma, Carbonic Anhydrase Inhibitors
  • Diuretics, Loop
  • Diuretics, Other
  • Diuretics, Thiazide
  • Diuretics, Potassium-Sparing
  • Vasopressin Antagonists
  • Show All
• References

encoded search term (Diuretics and Heart Failure) and Diuretics and Heart Failure What to Read Next on Medscape Related Conditions and Diseases

• Heart Failure
• Pediatric Congestive Heart Failure
• Diuretics and Heart Failure
• Congestive Heart Failure Imaging
• Natriuretic Peptides in Congestive Heart Failure
• Reducing Hospitalization in Heart Failure
• The Risks of Hospitalization for Heart Failure

News & Perspective

• ‘A Turning Point’ in Heart Failure
• 'Obesity Paradox' in Heart Failure Debunked
• In Heart Failure, Cellular Therapy Is Active
• Feb 20, 2026 This Week in Cardiology Podcast
• Frailty in Cardiovascular Disease
• Feb 13, 2026 This Week in Cardiology Podcast

Tools

• Drug Interaction Checker
• Calculators
• Formulary

Slideshow On Strike or Working Overtime: 13 Endocrine Emergencies Recommended

• 2002 163062-overview Diseases & Conditions Diseases & Conditions Heart Failure
• 2002 2069746-overview Diseases & Conditions Diseases & Conditions Pediatric Congestive Heart Failure
• 2002 2145340-overview Procedures Procedures Diuretics and Heart Failure
• 2001 https://www.medscape.com/viewarticle/turning-point-heart-failure-2025a10004wx news news ‘A Turning Point’ in Heart Failure
• 2001 https://www.medscape.com/viewarticle/obesity-paradox-heart-failure-debunked-2023a100060e news news 'Obesity Paradox' in Heart Failure Debunked
• 2001 https://www.medscape.com/viewarticle/heart-failure-cellular-therapy-active-2025a10009jz news news In Heart Failure, Cellular Therapy Is Active